Shares of FibroGen Inc. (NASDAQ:FGEN) rose 3.6% on Thursday . The stock traded as high as $18.30 and last traded at $18.27, with a volume of 168,494 shares changing hands. The stock had previously closed at $17.64.

A number of analysts have recently commented on FGEN shares. Credit Suisse Group AG reissued a “buy” rating and issued a $38.00 price target on shares of FibroGen in a research report on Tuesday, May 10th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $33.50.

The stock’s market capitalization is $1.12 billion. The firm has a 50-day moving average price of $17.08 and a 200 day moving average price of $18.92.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.11. Equities research analysts anticipate that FibroGen Inc. will post ($1.02) earnings per share for the current year.

In related news, insider K Peony Yu sold 2,344 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $17.96, for a total value of $42,098.24. Following the sale, the insider now directly owns 210,257 shares of the company’s stock, valued at approximately $3,776,215.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 27,000 shares of the stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $17.78, for a total transaction of $480,060.00. Following the completion of the sale, the chief executive officer now directly owns 3,552,353 shares in the company, valued at $63,160,836.34. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of FGEN. PNC Financial Services Group Inc. raised its position in shares of FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 35,346 shares during the period. Rhumbline Advisers raised its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares during the period. Nationwide Fund Advisors raised its position in shares of FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 393 shares during the period. ProShare Advisors LLC bought a new position in shares of FibroGen during the fourth quarter worth approximately $1,715,000. Finally, Swiss National Bank raised its position in shares of FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares during the period.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.